Ex-Biotech CEO to Pay SEC More Than $1.1 Million

A former Transkaryotic Therapies executive agreed to pay more than $1.1 million to settle claims that he misled investors about problems facing the Cambridge biotech company's flagship drug, the government said.
Boston.com